Potential limited cross-drug reaction among fluoroquinolones: A large database analysis by International Classification of Diseases, Tenth Revision code-based approach
Journal of Allergy and Clinical Immunology: Global · 2026-11 · 5 (6) · 100783
DOI: 10.1016/j.jacig.2026.100783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2026-11. Verfasst von Chia-Yu Chiu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora, Colo. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Fluoroquinolone allergy is the third most commonly reported antibiotic allergy. Cross-drug reactions among fluoroquinolones remain a clinical concern, although existing studies are limited by small sample sizes and a lack of control groups.
Objective
We aimed to assess the real-world frequency and risk of potential fluoroquinolone cross-drug reactions using a large health care database.
Methods
We performed a retrospective analysis using the TriNetX database in September 2025. Patients with an allergy label to ciprofloxacin, levofloxacin, or moxifloxacin who were subsequently exposed to a different fluoroquinolone were identified. Potential cross-drug reactions following the second fluoroquinolone exposure were assessed based on the International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes. Odds ratios for potential cross-drug reactions were calculated.
Results
The frequencies of potential cross-drug reactions following a second fluoroquinolone exposure were as follows: 2.6% (index allergy to ciprofloxacin, subsequent allergy to levofloxacin), 1.5% (ciprofloxacin → moxifloxacin), 2.7% (levofloxacin → ciprofloxacin), 1.3% (levofloxacin → moxifloxacin), 2.9% (moxifloxacin → ciprofloxacin), and 2.9% (moxifloxacin → levofloxacin). Compared with patients without an index fluoroquinolone allergy, the odds of experiencing a potential cross-drug reaction were slightly higher in some drug pairs: 1.18 (ciprofloxacin → levofloxacin; 95% confidence interval [CI] 1.06-1.31; P < .05), 1.12 (levofloxacin → ciprofloxacin; 95% CI, 1.01-1.23; P < .05), and 1.31 (moxifloxacin → ciprofloxacin; 95% CI, 1.12-1.54; P < .05).
Conclusion
Potential cross-drug reactions between ciprofloxacin, levofloxacin, and moxifloxacin were rare (∼2%) and slightly increased the odds of subsequent reaction in some drug pairs. These findings suggest class-wide avoidance may be unnecessary and support drug challenge as a safe strategy in selected patients. Interpretation of our findings should be cautious, as this is an International Classification of Diseases, Tenth Revision code-based approach without detailed mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, University of Colorado, Aurora, Colo.
- Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Augusta, Ga.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colo.
Zitieren
APA
Chiu, C. Y., Chastain, D. B., Jeffres, M. N., & Henao-Martínez, A. F. (2026). Potential limited cross-drug reaction among fluoroquinolones: A large database analysis by International Classification of Diseases, Tenth Revision code-based approach. Journal of Allergy and Clinical Immunology: Global, 5(6), 100783. https://doi.org/10.1016/j.jacig.2026.100783
Vancouver
Chiu CY, Chastain DB, Jeffres MN, Henao-Martínez AF. Potential limited cross-drug reaction among fluoroquinolones: A large database analysis by International Classification of Diseases, Tenth Revision code-based approach. Journal of Allergy and Clinical Immunology: Global. 2026;5(6):100783. doi:10.1016/j.jacig.2026.100783
BibTeX
@article{Chiu2026,
author = {Chiu, Chia-Yu and Chastain, Daniel B and Jeffres, Meghan N and Henao-Martínez, Andrés F},
title = {Potential limited cross-drug reaction among fluoroquinolones: A large database analysis by International Classification of Diseases, Tenth Revision code-based approach},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2026},
volume = {5},
number = {6},
pages = {100783},
doi = {10.1016/j.jacig.2026.100783}
}
EUVIMED